Form D · Pharmaceuticals

Medexus Pharmaceuticals Inc.

Verdun, A8 · CIK 0001806605

Offering snapshot reported Mar 13, 2020 · SEC filing

Reported sold: $400K
Investors reported: 1
Minimum accepted: $0
First sale: Feb 28, 2020

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 13, 2020	Initial	$400,000	No comparison	1	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired, Other
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-362803

The additional $400,000 may be received upon the exercise of share purchase warrants sold inside or outside the U.S. U.S. dollars amounts are based on the Bank of Canada average rate of exchange reported on 2/28/2020, which was Cdn$1.3429=USD$1.00.

Each Warrant entitles its holders to purchase 1 common share ("CS") at Cdn$4.00 per CS until the earlier of (a) 2/1/2024 and (b) the date that is 91 days prior to the maturity of the 2023 convertible notes unless such notes have been converted into CS.

Source: Form D, filed Mar 13, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Roland Boivin	Executive
Ken D'entremont	Director, Executive
Benoit Gravel	Director
Adele Gulfo	Director
Michael Mueller	Director
Stephen Nelson	Director
Terri Shoemaker	Executive
Peter Van Der Velden	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

225 1 Place Du Commerce
Verdun, A8, H3E 1A2